However, the analyses were often not adjusted for CD4 nadir, while it is associated both with the risk of anal cancer and ARV treatment initiated with a PI‐based regimen at treatment initiation nor adjusted for the whole ARV treatment history. The gene discussed is CD4; the disease is anal carcinoma.